The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.
Lecia V. Sequist
Consultant or Advisory Role - Clovis (U)
Research Funding - Clovis
Jean-Charles Soria
Research Funding - Clovis
Shirish M. Gadgeel
Research Funding - Clovis
Heather A. Wakelee
Research Funding - Clovis
D. Ross Camidge
Honoraria - Clovis
Research Funding - Clovis
Andrea Varga
Research Funding - Clovis
Panos Fidias
Research Funding - Clovis
Antoinette J. Wozniak
Research Funding - Clovis
Joel W. Neal
Research Funding - Clovis
Robert Charles Doebele
Research Funding - Clovis
Edward B. Garon
Research Funding - Clovis
Sarah S. Jaw-Tsai
Employment or Leadership Position - Clovis
Consultant or Advisory Role - Clovis
Stock Ownership - Clovis
Jennifer C. Stern
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Andrew R. Allen
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Jonathan Wade Goldman
Honoraria - Clovis
Research Funding - Clovis